Supermarket’s big bet on GLP-1s


A major Australian retailer is shifting its strategy in line with changing health patterns and demands Woolworths expects up to one in four Australians will be on glucagon-like peptide-1 receptor agonists (GLP-1s) in the next four years and is realigning its health range to adjust to the uptake. According to the company’s internal modelling, between

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous World news wrapup: 19 November 2026
This is the most recent story.